Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 5/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21461372 | 1.00 | BHMT (0.38) | BHMTNOS2NOS1NOS3ARG1 | |
| SCHEMBL23586891 | 1.00 | BHMT (0.38) | BHMTNOS2NOS1NOS3ARG1 | |
| SCHEMBL17234319 | 1.00 | BHMT (0.38) | BHMTNOS2NOS1NOS3ARG1 | |
| SCHEMBL21461373 | 0.86 | BHMT (0.48) | BHMTNOS2NOS1NOS3 | |
| SCHEMBL21461374 | 0.86 | BHMT (0.48) | BHMTNOS2NOS1NOS3 | |
| SCHEMBL23586839 | 0.86 | BHMT (0.48) | BHMTNOS2NOS1NOS3 | |
| SCHEMBL17234324 | 0.86 | BHMT (0.48) | BHMTNOS2NOS1NOS3 | |
| SCHEMBL23586885 | 0.83 | — | — | |
| SCHEMBL24241853 | 0.81 | BHMT (0.40) | BHMTNOS2NOS1NOS3ARG1 | |
| SCHEMBL18528398 | 0.81 | BHMT (0.40) | BHMTNOS2NOS1NOS3ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | BHMT 505/4885NOS2 3755/4885NOS1 3768/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | BHMT 902/4885NOS2 3782/4885NOS1 3763/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | BHMT 902/4885NOS2 3782/4885NOS1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.